With the help and support of Jiangsu Ke Mei Pharmaceutical Technology Co., Ltd., the research team successfully developed a reagent for detecting IgM-IgG binding antibody in novel coronavirus. The clinical samples of patients with coronavirus pneumonia-19 were tested in tertiary hospitals and national provincial centers for disease control and prevention, and the detection sensitivity, specificity and clinical application value of this reagent were verified. It is reported that the detection reagent can be detected only by dropping blood, and the result can be obtained in about 15 minutes, which greatly reduces the detection time (RT-PCR detection of virus nucleic acid takes 3-4 hours to obtain the result). The sensitivity of the detection reagent to clinical detection is as high as 88.66% and the specificity of detection is 90.63%.
The sensitivity of IgM-IgG combined antibody detection is much higher than that of IgM or IgG alone and antibody detection (sensitivity 94.83% vs 1.72% and 3.45%). In addition, the antibody detection reagent compared the results of fingertip blood and venous blood, and found that the consistency of the two tests was basically the same. It is suggested to use novel coronavirus IgM-IgG binding antibody rapid detection kit as instant detection (POCT). You can take blood with your fingertips at the bedside for examination, which indicates a more convenient screening method. The antibody detection kit for coronavirus pneumonia-19 has the advantages of convenience (blood drop test), rapidity (15 minutes), safety (no direct contact with respiratory virus), high detection sensitivity (IgM-IgG binding antibody), etc. It is a supplementary detection for patients with negative viral nucleic acid and can improve the clinical diagnosis rate.
It can also be used as a rapid screening method to give full play to the advantages of screening during large-scale migration and recovery, such as restoring the domestic labor force. Zhong Nanshan first introduced the basic characteristics of this new epidemic virus, including its gene sequence, the nature of human-to-human transmission and various transmission routes. When it comes to detecting new viruses, Zhong Nanshan introduced the rapid IgM (immunoglobulin M) test paper developed by the team as an auxiliary means of nucleic acid detection. He also introduced the application of isothermal amplification chip, which can help inspectors to distinguish novel coronavirus, influenza A virus and influenza B virus. According to the condition of some newly cured patients with coronary heart disease in Fuyang, Zhong Nanshan thinks that the IgG antibody content of the cured patients has greatly increased. In this case, the test results are unlikely to be attributed to the recurrence of Fuyang virus. It is not clear whether the nucleic acid test of Fuyang patients is still contagious. Zhong Nanshan suggested that the medical staff should continue the isolation examination after discharge.